Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
2022 · Cancer Cell · 336 citations
https://doi.org/10.1016/j.ccell.2022.07.002
N
Nicola Long
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
325
Papers
2.7K
Citations
15
h-index
15
i10-index
Nicola Long is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Chronic Myeloid Leukemia Treatments & Cancer therapeutics and mechanisms. The author has an h-index of 15, co-authored 277 publications.
ORCID: 0000-0002-9010-8167Papers by this author
worksNGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia
2023 · Blood Cancer Journal · 21 citations
https://doi.org/10.1038/s41408-023-00833-7
Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia
2024 · Cell Reports Medicine · 17 citations
https://doi.org/10.1016/j.xcrm.2023.101359
Data from Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
2024 · 0 citations
https://doi.org/10.1158/1541-7786.c.6606916.v3
Supplementary Table 7 from Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
2024 · 0 citations
https://doi.org/10.1158/1541-7786.27034564
Supplementary Table 14 from Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
2024 · 0 citations
https://doi.org/10.1158/1541-7786.27034597
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat